OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with
OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • patients with unresectable or metastatic melanoma, as a single agent or in combination...
OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following...
• OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.
2024年6月28日 · OPDIVO is used in adult patients to help prevent cancer of the urinary tract from coming back after it was removed by surgery. OPDIVO may be used in combination with chemotherapy medicines cisplatin and gemcitabine as your first
When OPDIVO is given in combination with ipilimumab for the treatment of skin cancer in adults and adolescents 12 years of age and older, the recommended dose of OPDIVO is 1 mg of nivolumab per kilogram of your body weight for the first 4 doses (combination phase).
OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma •adult and pediatric 12 years and older( ) patients with unresectable or metastatic...
o OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable, advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression in ≥ 1% of the tumor cells.
OPDIVO, in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)] . This indication is approved under...
Read this Medication Guide before you start receiving OPDIVO and before each infusion. There may be new information. If your healthcare provider prescribes OPDIVO in combination with ipilimumab, also read the Medication Guide that comes with ipilimumab.
- 某些结果已被删除